Mechanism of Musashi2 affecting radiosensitivity of lung cancer by modulating DNA damage repair

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Tumor radioresistance is a major obstacle in lung cancer radiotherapy.
• Musashi2 (MSI2) has emerged as a significant factor in cancer biology.
• Identifying novel targets to overcome radioresistance is critical for improving patient outcomes.

Purpose of the Study:

• To investigate the role of Musashi2 (MSI2) in regulating lung cancer radiosensitivity.
• To explore the molecular mechanisms by which MSI2 influences DNA damage response and radioresistance.
• To evaluate MSI2 as a potential therapeutic target for enhancing lung cancer radiotherapy.

Main Methods:

• Assessed MSI2 expression correlation with overall survival in lung cancer patients.
• Performed MSI2 knockdown experiments to evaluate effects on radiosensitivity and tumorigenesis.
• Investigated MSI2 interactions with ATR and CHK1 post-irradiation.
• Examined the role of RNA-binding motif protein 17 (RBM17) in MSI2-mediated radioresistance.

Main Results:

• MSI2 expression negatively correlates with overall survival in lung cancer patients.
• MSI2 knockdown inhibits lung cancer cell tumorigenesis and increases radiosensitivity.
• MSI2 interacts with ATR and CHK1, influencing the DNA damage response pathway.
• RBM17 facilitates MSI2 nuclear recruitment and ATR activation, promoting radioresistance; RBM17 knockdown increases radiosensitivity.

Conclusions:

• MSI2 plays a crucial role in promoting lung cancer radioresistance.
• MSI2's interaction with ATR, facilitated by RBM17, is a key mechanism driving radioresistance.
• Targeting MSI2 presents a promising strategy for overcoming radioresistance in lung cancer radiotherapy.